Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 25 条

[11] Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
Zheng, Jing
Wang, Tao
Yang, Yunpeng
Huang, Jie
Feng, Jifeng
Zhuang, Wu
Chen, Jianhua
Zhao, Jun
Zhong, Wei
Zhao, Yanqiu
Zhang, Yiping
Song, Yong
Hu, Yi
Yu, Zhuang
Gong, Youling
Chen, Yuan
Ye, Feng
Zhang, Shucai
Cao, Lejie
Fan, Yun
Wu, Gang
Guo, Yubiao
Zhou, Chengzhi
Ma, Kewei
Fang, Jian
Feng, Weineng
Liu, Yunpeng
Zheng, Zhendong
Li, Gaofeng
Wang, Huijie
Cang, Shundong
Wu, Ning
Song, Wei
Liu, Xiaoqing
Zhao, Shijun
Ding, Lieming
Selvaggi, Giovanni
Wang, Yang
Xiao, Shanshan
Wang, Qian
Shen, Zhilin
Zhou, Jianya
Zhou, Jianying
Zhang, Li
CANCER COMMUNICATIONS, 2024, 44 (04) : 455 - 468
[12] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
Ahn, M. -J.
Delmonte, A.
Ghosh, S.
Hochmair, M.
Yang, T. -Y.
Yang, J. C. -H.
Han, J. -Y.
Hansen, K. Holmskov
Wu, Y.
Wan, Y.
Lin, H. M.
Kretz, J.
Hupf, B.
Kurec, A. M.
Churchill, E. N.
Fram, R. J.
Cabasag, C. J.
Goriya, V.
Zhao, Y.
Gemmen, E.
Campelo, M. R. Garcia
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
[13] Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L)
Garcia Campelo, Maria Rosario
Lin, Huamao M.
Zhu, Yanyan
Perol, Maurice
Jahanzeb, Mohammad
Popat, Sanjay
Zhang, Pingkuan
Camidge, D. Ross
LUNG CANCER, 2021, 155 : 68 - 77
[14] From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee, Alexandria T. M.
Ou, Saihong Ignatius
LUNG CANCER-TARGETS AND THERAPY, 2023, 14 : 57 - 62
[15] Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial
Hida, T.
Katayama, R.
Nishio, M.
Yoshida, T.
Kumagai, T.
Toyozawa, R.
Shimokawaji, T.
Goto, K.
Nakagawa, K.
Seto, T.
Yamamoto, N.
Asato, T.
Hiraoka, K.
Zhang, P.
Ohe, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S572 - S572
[16] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
Nishio, Makoto
Yoshida, Tatsuya
Kumagai, Toru
Hida, Toyoaki
Toyozawa, Ryo
Shimokawaji, Tadasuke
Goto, Koichi
Nakagawa, Kazuhiko
Ohe, Yuichiro
Seto, Takashi
Kudou, Kentarou
Asato, Takayuki
Zhang, Pingkuan
Yamamoto, Nobuyuki
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
[17] Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
Yoshida, Tatsuya
Kumagai, Toru
Toyozawa, Ryo
Katayama, Ryohei
Nishio, Makoto
Seto, Takashi
Goto, Koichi
Yamamoto, Nobuyuki
Ohe, Yuichiro
Kudou, Kentarou
Asato, Takayuki
Zhang, Pingkuan
Nakagawa, Kazuhiko
CANCER SCIENCE, 2023, 114 (09) : 3698 - 3707
[18] TSR-011: A POTENT INHIBITOR OF ALK INCLUDING CRIZOTINIB-RESISTANT MUTATIONS IN PHASE 1-2 DEVELOPMENT FOR ALK plus NSCLC
Weiss, Glen J.
Sachdev, Jasgit C.
Infante, Jeffrey R.
Mita, Monica
Wilcoxen, Keith M.
Kansra, Vikram
Brooks, David G.
Martell, Robert E.
Anthony, Stephen P.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S618 - S618
[19] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
Horn, Leora
Wakelee, Heather
Reckamp, Karen
Blumenschein, George
Infante, Jeffrey
Carter, Corey
Waqar, Saiama
Neal, Joel
Gockerman, Jon
Harrow, Kimberly
Dukart, Gary
Liang, Chris
Gibbons, James
Hernandez, Jennifer
Newman-Eerkes, Tera
Lim, Lee
Lovly, Christine
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1159 - S1159
[20] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238

← 1 2 3 →